Establish Predictive CQAs Through Advanced Characterization & Heterogeneity Analysis
- Moving beyond particle size and reassessing CQAs for next-generation LNP therapeutics
- How should CQA strategies differ between discovery, IND-enabling, and commercial stages?
- How do we connect analytical attributes to potency, safety, and efficacy?